Effect of Intravenous S-ketamine on Opioid Consumption

• Status: Not yet recruiting
• Trial end date: 2022-07-07
• Target enrollment: 0
• Participant gender: Female

Summary

Female patients with an American Society of Anesthesia (ASA) physical status I-II, scheduled for elective breast cancer surgery will be included in the study. Subjects will be randomly assigned to one of three groups: the placebo group, the low-dose S-ketamine group, and the high-dose S-ketamine group. The primary outcome is the consumption of sufentanil during the surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Second Hospital of Anhui Medical University
• Treatments: Esketamine; Ketamine

Criteria

Inclusion Criteria:

1. Female patients with an American Society of Anesthesia (ASA) physical status I-II

2. Scheduled for elective breast cancer surgery

Exclusion Criteria:

1. Patients unable to understand the study procedure or unable to give informed consent

2. with concurrent analgesic or sedative medication,

3. with history of chronic pain

4. with history of psychiatric disorders

5. with history of alcohol or drug abuse

6. with an allergy to the study medication

7. who are pregnant or breast feeding

8. with a BMI >30 and <18 kg/m^2

9. with severe cardiac, pulmonary, hepatic or renal dysfunction

10. with intracranial hypertension